News

Dewpoint Therapeutics announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint's discovery platform related to biomolecular…
Read More...

Invitae and Deerfield Management Company announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and…
Read More...

The European Commission (EC) has approved Dupixent (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates…
Read More...

Gilead Sciences, Inc. and Nurix Therapeutics, Inc. announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule…
Read More...

Coya Therapeutics, Inc. a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today…
Read More...

Predictive Oncology Inc. together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK),…
Read More...

Arrowhead Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with…
Read More...

Syneos Health announced a strategic multi-year agreement with Microsoft. Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables…
Read More...

BioNTech SE and OncoC4, Inc. announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation…
Read More...

Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a…
Read More...

Ipsen announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational…
Read More...

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, announced a…
Read More...

Processa Pharmaceuticals, Inc. announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa…
Read More...

Alphamab Oncology announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the…
Read More...

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the…
Read More...

Ipsen announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational…
Read More...

Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and…
Read More...

Novartis announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of pediatric patients 1 year of age…
Read More...

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the…
Read More...

Prelude Therapeutics Incorporated (Prelude) announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination…
Read More...